Clinical Trial Update: A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating ALN-CC5 in healthy volunteers and patients with Paroxysmal Nocturnal Hemoglobinuria (PNH); study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• ALN-CC5 (ALN-CC5)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-30